1-14 of 14
Lynn M. Schuchter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival

Kevin L. Ma, Tara C. Mitchell, Meaghan Dougher, Cimarron E. Sharon, Gabriella N. Tortorello, David E. Elder, Eric E. Morgan, Phyllis A. Gimotty, Alexander C. Huang, Ravi K. Amaravadi, Lynn M. Schuchter, Ahron Flowers, John T. Miura, Giorgos C. Karakousis, Xiaowei Xu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4987–4994.
https://doi.org/10.1158/1078-0432.CCR-23-3775
Published: 01 November 2024
View article titled, Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival
Open the PDF for Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival in another window
Includes: Supplementary data
Journal Articles

FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Thomas M. Anderson, Bryan H. Chang, Alexander C. Huang, Xiaowei Xu, Daniel Yoon, Catherine G. Shang, Rosemarie Mick, Erin Schubert, Suzanne McGettigan, Kristin Kreider, Wei Xu, E. John Wherry, Lynn M. Schuchter, Ravi K. Amaravadi, Tara C. Mitchell, Michael D. Farwell
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1758–1767.
https://doi.org/10.1158/1078-0432.CCR-23-2390
Published: 01 May 2024
View article titled, FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Open the PDF for FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Ángel Berciano-Guerrero, Eva Muñoz Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez-Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas O. Iannotti, Frank J. Hsu, Harriet M. Kluger
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 74–81.
https://doi.org/10.1158/1078-0432.CCR-23-0475
Published: 05 January 2024
View article titled, A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Open the PDF for A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy in another window
Includes: Supplementary data
Journal Articles

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma

Janice M. Mehnert, Tara C. Mitchell, Alexander C. Huang, Tomas S. Aleman, Benjamin J. Kim, Lynn M. Schuchter, Gerald P. Linette, Giorgos C. Karakousis, Sheryl Mitnick, Lydia Giles, Mary Carberry, Noelle Frey, Andrew Kossenkov, Roman Groisberg, Leonel F. Hernandez-Aya, George Ansstas, Ann W. Silk, Sunandana Chandra, Jeffrey A. Sosman, Phyllis A. Gimotty, Rosemarie Mick, Ravi K. Amaravadi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1098–1106.
https://doi.org/10.1158/1078-0432.CCR-21-3382
Published: 15 March 2022
View article titled, BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced <em>BRAFV600</em>-mutant Melanoma
Open the PDF for BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced <em>BRAFV600</em>-mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

Gao Zhang, Lawrence W. Wu, Ilgen Mender, Michal Barzily-Rokni, Marc R. Hammond, Omotayo Ope, Chaoran Cheng, Themistoklis Vasilopoulos, Sergio Randell, Norah Sadek, Aurelie Beroard, Min Xiao, Tian Tian, Jiufeng Tan, Umar Saeed, Eric Sugarman, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Sengottuvelan Murugan, Rajasekharan Somasundaram, Bradley Garman, Bradley Wubbenhorst, Jonathan Woo, Xiangfan Yin, Qin Liu, Dennie T. Frederick, Benchun Miao, Wei Xu, Giorgos C. Karakousis, Xiaowei Xu, Lynn M. Schuchter, Tara C. Mitchell, Lawrence N. Kwong, Ravi K. Amaravadi, Yiling Lu, Genevieve M. Boland, Zhi Wei, Katherine Nathanson, Utz Herbig, Gordon B. Mills, Keith T. Flaherty, Meenhard Herlyn, Jerry W. Shay
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4771–4784.
https://doi.org/10.1158/1078-0432.CCR-17-2773
Published: 01 October 2018
View article titled, Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Open the PDF for Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma in another window
Includes: Multimedia, Supplementary data
Journal Articles

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors

Clinton Yam, Xiaowei Xu, Michael A. Davies, Phyllis A. Gimotty, Jennifer J.D. Morrissette, Michael T. Tetzlaff, Khalida M. Wani, Shujing Liu, Wanleng Deng, Meghan Buckley, Jianhua Zhao, Ravi K. Amaravadi, Naomi B. Haas, Ragini R. Kudchadkar, Anna C. Pavlick, Jeffrey A. Sosman, Hussein Tawbi, Luke Walker, Lynn M. Schuchter, Giorgos C. Karakousis, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 22–32.
https://doi.org/10.1158/1078-0432.CCR-17-1807
Published: 02 January 2018
View article titled, A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Open the PDF for A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Clemens Krepler, Min Xiao, Katrin Sproesser, Patricia A. Brafford, Batool Shannan, Marilda Beqiri, Qin Liu, Wei Xu, Bradley Garman, Katherine L. Nathanson, Xiaowei Xu, Giorgos C. Karakousis, Gordon B. Mills, Yiling Lu, Tamer A. Ahmed, Poulikos I. Poulikakos, Giordano Caponigro, Markus Boehm, Malte Peters, Lynn M. Schuchter, Ashani T. Weeraratna, Meenhard Herlyn
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1592–1602.
https://doi.org/10.1158/1078-0432.CCR-15-1762
Published: 31 March 2016
View article titled, Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Open the PDF for Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies in another window
Includes: Supplementary data
Journal Articles

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma

Melissa A. Wilson, Fengmin Zhao, Sanika Khare, Jason Roszik, Scott E. Woodman, Kurt D'Andrea, Bradley Wubbenhorst, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Lynn M. Schuchter, Sandra J. Lee, Keith T. Flaherty, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 374–382.
https://doi.org/10.1158/1078-0432.CCR-15-1162
Published: 14 January 2016
View article titled, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma
Open the PDF for Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma in another window
Includes: Supplementary data
Journal Articles

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors

Ravi K. Amaravadi, Kathryn E. Hamilton, Xiaohong Ma, Shengfu Piao, Armando Del Portillo, Katherine L. Nathanson, Matteo S. Carlino, Georgina V. Long, Igor Puzanov, Xiaowei Xu, Jennifer J.D. Morrissette, Kenneth Y. Tsai, Keith T. Flaherty, Jeffrey A. Sosman, Grant R. Goodman, Grant A. McArthur, Anil K. Rustgi, David C. Metz, Lynn M. Schuchter, Paul B. Chapman, Antonia R. Sepulveda
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5215–5221.
https://doi.org/10.1158/1078-0432.CCR-15-0469
Published: 30 November 2015
View article titled, Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Open the PDF for Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors in another window
Includes: Supplementary data
Journal Articles

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Tao Wang, Min Xiao, Yingbin Ge, Clemens Krepler, Eric Belser, Alfonso Lopez-Coral, Xiaowei Xu, Gao Zhang, Rikka Azuma, Qin Liu, Rui Liu, Ling Li, Ravi K. Amaravadi, Wei Xu, Giorgos Karakousis, Tara C. Gangadhar, Lynn M. Schuchter, Melissa Lieu, Sanika Khare, Molly B. Halloran, Meenhard Herlyn, Russel E. Kaufman
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (7): 1652–1664.
https://doi.org/10.1158/1078-0432.CCR-14-1554
Published: 31 March 2015
View article titled, BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Open the PDF for BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

Melissa A. Wilson, Fengmin Zhao, Richard Letrero, Kurt D'Andrea, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Sandra J. Lee, Lynn M. Schuchter, Keith T. Flaherty, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3328–3337.
https://doi.org/10.1158/1078-0432.CCR-14-0093
Published: 12 June 2014
View article titled, Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib
Open the PDF for Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

Ravi K. Amaravadi, Lynn M. Schuchter, David F. McDermott, Amy Kramer, Lydia Giles, Kristi Gramlich, Mary Carberry, Andrea B. Troxel, Richard Letrero, Katherine L. Nathanson, Michael B. Atkins, Peter J. O'Dwyer, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (24): 7711–7718.
https://doi.org/10.1158/1078-0432.CCR-09-2074
Published: 14 December 2009
View article titled, Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Open the PDF for Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases in another window
Journal Articles

Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers

Erica L. Carpenter, Rosemarie Mick, Andrew J. Rech, Gregory L. Beatty, Theresa A. Colligon, Myrna R. Rosenfeld, David E. Kaplan, Kyong-Mi Chang, Susan M. Domchek, Peter A. Kanetsky, Leslie A. Fecher, Keith T. Flaherty, Lynn M. Schuchter, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (13): 4277–4287.
https://doi.org/10.1158/1078-0432.CCR-09-0537
Published: 01 July 2009
View article titled, Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers
Open the PDF for Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers in another window
Journal Articles

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

Keith T. Flaherty, Joan Schiller, Lynn M. Schuchter, Glenn Liu, David A. Tuveson, Maryann Redlinger, Chetan Lathia, Chenghua Xia, Oana Petrenciuc, Sunil R. Hingorani, Michael A. Jacobetz, Patricia A. Van Belle, David Elder, Marcia S. Brose, Barbara L. Weber, Mark R. Albertini, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4836–4842.
https://doi.org/10.1158/1078-0432.CCR-07-4123
Published: 01 August 2008
View article titled, A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
Open the PDF for A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel in another window